Streetbeat News

Earnings

ADAUSD

BTCUSD

ETHUSD

HOOD

MATICUSD

SOLUSD

Robinhood Markets Inc's CEO, Vlad Tenev, discussed the company's performance in the cryptocurrency market during the Q3 earnings call. He acknowledged the strong performance of Bitcoin and Ethereum, but noted subdued volume trends. Tenev also revealed plans for Robinhood to expand its services into the European Union. He addressed the delisting of certain cryptocurrencies, including Cardano, Polygon, and Solana, stating that regulatory clarity is crucial in such decisions. Robinhood reported a 55% drop in crypto trading revenues to $23 million in Q3 2023.

Portfolio Pulse from Mehab Qureshi

November 08, 2023 | 5:17 am

BTCUSD

HOOD

Robinhood CEO Vlad Tenev expressed optimism about the future of Bitcoin and the potential for a Bitcoin ETF during the company's earnings call. He noted the increasing attractiveness of Bitcoin as a mainstream asset for diversification. However, Robinhood reported a drop in its crypto trading revenues during the third quarter, with transaction-based revenues on cryptocurrencies declining by 55% to $23 million.

Portfolio Pulse from Mehab Qureshi

November 08, 2023 | 4:14 am

SSTI

SoundThinking has reaffirmed its FY23 revenue guidance of $92M-$94M, representing a 15% YoY growth. The company expects its annual recurring revenue (ARR) on 12/31/2023 to have increased over 17% to approximately $93.5 million. The company's financial outlook statements are based on current expectations and actual results could differ materially depending on market conditions.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:46 am

OSUR

OraSure Technologies has provided its Q4 2023 revenue guidance, expecting to generate between $71M and $76M. This includes core revenue of $33M to $35M and InteliSwab® revenue of $38M to $41M. The company is also on track to exceed the $15M of annualized cost savings announced in Q1 2023.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:45 am

PSNL

Personalis has updated its Q4 2023 revenue forecast to $19M-$20M, higher than the estimated $18.12M. The company also expects FY23 revenue to be between $73M-$74M, surpassing the $70.6M estimate. The increase in revenue is attributed to pharma tests, enterprise sales, and other customers. The company also expects a net loss of approximately $103M, a reduction from $113M in 2022, due to headcount reduction savings and other factors.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:44 am

HCKT

The Hackett Group has provided its Q4 2023 business outlook, estimating total revenue before reimbursements to be between $69.0 million and $70.4 million, and adjusted diluted earnings per share to be between $0.36 and $0.38. These estimates are lower than the previous estimates of $73.29 million revenue and $0.39 EPS.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:42 am

OM

Outset Medical has reiterated its 2023 revenue guidance of approximately $130 million, which is slightly lower than the estimated $132 million. The company also maintains its gross margin guidance for the year to be in the low-20% range, exiting the fourth quarter in the mid-20% range.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:41 am

EOLS

Evolus has updated its FY23 revenue forecast to $194M-$198M, exceeding the previous estimate of $190.81M. This represents a YoY growth of over 30%. The company also expects its adjusted gross profit margin for FY23 to be between 68% and 71%, and its full-year non-GAAP operating expenses to be between $153M and $158M. Evolus projects its total net revenue can reach $700 million by 2028, a CAGR of 29%, driven by its existing aesthetic neurotoxin business and the anticipated launch of the Evolysse™ HA dermal filler product line in 2025.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:40 am

ENVX

Enovix Corporation (ENVX) expects Q4 2023 revenue to increase to between $3 million and $4 million, up from an estimated $530K, due to partial quarter from Routejade and continued shipments of silicon batteries for the U.S. Army program. The company also revised its operational cash use forecast for 2023 from $120 million to $110 million and CapEx forecast from $70 million to $65 million due to strategic realignment of Fab1 and timing of Gen2 equipment installation in Malaysia.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:39 am

ODD

Oddity Tech has raised its FY23 EPS from $1.11-$1.17 to $1.21-$1.23, and revenue from $475M-$480M to $493M-$497M. This is due to strong Q3 results, leading to higher revenue, profit margins, and earnings than previously expected. The company now expects year-over-year growth between 52% and 53%, gross margins of approximately 70.0%, and adjusted EBITDA between $104 million and $105 million.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 1:37 am